4:55 PM
 | 
Aug 27, 2013
 |  BC Extra  |  Company News

Catalyst receives breakthrough designation for Firdapse

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) gained $0.59 (42%) to $2.01 on Tuesday after FDA granted breakthrough therapy designation to Firdapse amifampridine to treat Lambert-Eaton myasthenic syndrome...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >